Abstract： Objective： To observe the short- term effect of Chinese herbal medicine combined with targeted drugs for patients with middle-advanced non-small cell lung cancer of qi deficiency with blood stasis type. Methods ： A total of 73 cases of patients with middle-advanced non-small cell lung cancer were selected and divided into the study group and the control group according to the random number table method，37 and 36 cases in each group respectively. The control group was given the oral administration of the targeted drug gefitinib，and the study group was additionally treated with Yiqi Huoxue Jiedu tang based on the treatment of the control group. Both groups were treated for two months. The changes in the contents of tumor markers including carcinoembryonic antigen(CEA) ， carbohydrate antigens(CA125) and cytokeratin 19 fragment antigen 21- 1(Cyfra21- 1) in serum before and after treatment as well as the clinical effect in the two groups were observed and compared. The cancer- related fatigue degree in the two groups was evaluated by Multidimensional Fatigue Symptom Scale-Short Form(MFSI-SF)，and the quality of life was evaluated by Karnofsky Performance Status(KPS). Results：The control rate was 100% in the study group and 88.89% in the control group，the difference being significant(P＜ 0.05). After treatment， the contents of CEA， CA125 and Cyfra21- 1 in serum in the two groups were decreased when compared with those before treatment(P＜0.05)，and all the above indexes in study group were lower than those in control group(P＜0.05). After treatment， MFSI- SF scores in the two groups were decreased when compared with those before treatment(P＜0.05)，and KPS scores were increased(P＜0.05)；the MFSI-SF score in the study group was lower than that in the control group(P＜0.05)， and the KPS score was higher(P＜0.05). Conclusion： The therapy of Yiqi Huoxue Jidu tang combined with targeted drugs has a good short-term effect on patients with patients with middle-advanced non-small cell lung cancer of qi deficiency with blood stasis type， which can reduce the concentration of serum tumor markers， reduce cancer-related fatigue degree and improve the quality of life.